Treating to the target of remission in early rheumatoid arthritis is cost-effective: Results of the DREAM registry

BMC Musculoskeletal Disorders

Volumn 14, Issue , 2013, Pages

  Vermeer, Marloes ^a,b   Kievit, Wietske ^c   Kuper, Hillechiena H ^b   Braakman Jansen, Louise M A ^a   Bernelot Moens, Hein J ^d   Zijlstra, Theo R ^e   Den Broeder, Alfons A ^e   Van Riel, Piet L C M ^c   Fransen, Jaap ^c   Van De Laar, Mart A F J ^a,b  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d TWENTEBORG HOSPITAL   (Netherlands)

^e Department of Rheumatology Isala Klinieken ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DAS28; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; REMISSION; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; REGISTRIES; REMISSION INDUCTION; SULFASALAZINE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84889983501     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-14-350     Document Type: Article

References (31)

1. Treating rheumatoid arthritis to target recommendations of an international task force. Smolen JS, Aletaha D, Bijlsma JW, et al. Ann Rheum Dis 2010 69 631 637 10.1136/ard.2009.123919 20215140
2. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Schoels M, Knevel R, Aletaha D, et al. Ann Rheum Dis 2010 69 638 643 10.1136/ard.2009.123976 20237123
3. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Knevel R, Schoels M, Huizinga TW, et al. Ann Rheum Dis 2010 69 987 994 10.1136/ard.2009.126748 20448280
4. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Schipper LG, van Hulst LT, Grol R, et al. Rheumatology (Oxford) 2010 49 2154 2164 10.1093/rheumatology/keq195 20671022
5. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, et al. Ann Rheum Dis 2010 69 65 69 10.1136/ard.2008.097683 19155234
6. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Soubrier M, Lukas C, Sibilia J, et al. Ann Rheum Dis 2011 70 611 615 10.1136/ard.2010.137695 21242235
7. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Schipper L, Vermeer M, Kuper H, et al. Ann Rheum Dis 2011 71 845 850 22210852
8. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Prevoo ML, van 't Hof MA, Kuper HH, et al. Arthritis Rheum 1995 38 44 48 10.1002/art.1780380107 7818570
9. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Vermeer M, Kuper HH, Hoekstra M, et al. Arthritis Rheum 2011 63 2865 2872 10.1002/art.30494 21647867
10. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. van Tuyl LH, Boers M, Lems WF, et al. Ann Rheum Dis 2010 69 807 812 10.1136/ard.2009.108027 19451137
11. Disability in rheumatoid arthritis in the era of biological treatments. Krishnan E, Lingala B, Bruce B, Fries JF, Ann Rheum Dis 2012 71 213 218 10.1136/annrheumdis-2011-200354 21953343
12. The impact of rheumatoid arthritis and treatment on patients' lives. Strand V, Khanna D, Clin Exp Rheumatol 2010 28 32 S40 20576223
13. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone. Korthals-de Bos I, Van Tulder M, Boers M, et al. J Rheumatol 2004 31 1709 1716 15338488 (Pubitemid 39202509)
14. The Nijmegen inception cohort of early rheumatoid arthritis. Welsing PM, van Riel PL, J Rheumatol Suppl 2004 69 14 21 15053447 (Pubitemid 38327486)
15. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arnett FC, Edworthy SM, Bloch DA, et al. Arthritis Rheum 1988 31 315 324 10.1002/art.1780310302 3358796 (Pubitemid 18091653)
16. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Fransen J, Creemers MC, Van Riel PL, Rheumatology (Oxford) 2004 43 1252 1255 10.1093/rheumatology/ keh297 15238643 (Pubitemid 39359299)
17. Methods for the economic evaluation of health care programmes, second edition. Cartwright WS, In Methods for the economic evaluation of health care programmes, second edition. Torrance. Oxford: Oxford University Press, Michael F, Drummond, Bernie O'B, Greg L, Stoddart, George W, 1997 J Ment Health Policy Econ 1999; 2: 43
18. EuroQol: the current state of play. Brooks R, Health Policy 1996 37 53 72 10.1016/0168-8510(96)00822-6 10158943 (Pubitemid 26191458)
19. Measurement of patient outcome in arthritis. Fries JF, Spitz P, Kraines RG, Holman HR, Arthritis Rheum 1980 23 137 145 10.1002/art.1780230202 7362664 (Pubitemid 10164318)
20. Measurement of disability in Dutch rheumatoid arthritis patients. Siegert CE, Vleming LJ, Vandenbroucke JP, Cats A, Clin Rheumatol 1984 3 305 309 10.1007/BF02032335 6488708 (Pubitemid 15072110)
21. Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Bansback N, Marra C, Tsuchiya A, et al. Arthritis Rheum 2007 57 963 971 10.1002/art.22885 17665482 (Pubitemid 47237321)
22. Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. Harrison MJ, Lunt M, Verstappen SM, et al. Health Qual Life Outcomes 2010 8 21 10.1186/1477-7525-8-21 20149253
23. Dutch Board of Health Insurances, Dutch Guideline for Cost Analyses 2010
24. Statistics Netherlands, Statistics Netherlands http://www.cbs.nl (accessed 28 November 2011
25. Raad voor Volksgezondheid en Zorg, Zinnige en Duurzame Zorg 2006
26. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Marra CA, Woolcott JC, Kopec JA, et al. Soc Sci Med 2005 60 1571 1582 10.1016/j.socscimed.2004.08.034 15652688 (Pubitemid 40126441)
27. Epidemiology and burden of illness of rheumatoid arthritis. Kvien TK, Pharmacoeconomics 2004 22 1 12 (Pubitemid 38269929)
28. The economic burden of rheumatoid arthritis: beyond health care costs. Zhang W, Anis AH, Clin Rheumatol 2011 30 Suppl 1 25 32 21360103
29. The burden of illness of rheumatoid arthritis. Boonen A, Severens JL, Clin Rheumatol 2011 30 Suppl 1 3 8 21359507
30. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Verstappen SM, Bijlsma JW, Verkleij H, et al. Arthritis Rheum 2004 51 488 497 10.1002/art.20419 15188338 (Pubitemid 38725152)
31. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? Neovius M, Simard JF, Askling J, Ann Rheum Dis 2011 70 1010 1015 10.1136/ard.2010.136812 21406455